ArticleMolecular neurobiology2026
Neuronal IL-18 Signaling in the Medial Habenula Contributes to Schizophrenia-Like Behavioral Deficits via ERK-Associated BDNF Suppression.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Current antipsychotics for schizophrenia (SCZ) are notably ineffective against the debilitating cognitive and negative symptoms, creating a major therapeutic gap. Neuroinflammation in the medial habenula (MHb) is implicated in SCZ; however, the underlying cell-type-specific mechanisms remain unknown. This study aimed to determine whether pathologically elevated neuronal interleukin-18 (IL-18) in the MHb contributes to schizophrenia-like behavioral abnormalities through ERK-associated downregulation of brain-derived neurotrophic factor (BDNF). Utilizing an MK-801-treated rat model, we adopted a multi-modal approach. Single-cell RNA sequencing was used to identify the cellular origin of pathological IL-18. We then combined neuron-specific viral manipulations to test functional involvement, chemogenetics to manipulate MHb neuronal activity, and ex vivo electrophysiology to measure neuronal excitability. Finally, targeted pharmacological interventions were used to test the functional contribution of this signaling pathway. MHb neurons exhibited marked hypoactivity and pathological changes in MK-801-treated rats. Single-cell RNA sequencing and histological analyses indicated that MHb neurons are the predominant cellular source of the pathological IL-18 signal in this model. Functionally, neuron-specific IL-18 overexpression was sufficient to induce schizophrenia-like behavioral abnormalities, whereas its knockdown ameliorated negative-like and cognitive deficits. Mechanistically, our data support a model in which elevated neuronal IL-18 is associated with ERK overactivation, reduced BDNF expression, and neuronal hypoactivity. Furthermore, pharmacological inhibition of the ERK pathway in the MHb ameliorated deficits at the molecular (BDNF), cellular (neuronal firing), and behavioral levels. Our findings support a neuron-centered IL-18/ERK/BDNF signaling framework in the MHb that contributes to schizophrenia-like pathological changes in this model and warrants further preclinical investigation as a potential target for cognitive and negative symptoms relevant to schizophrenia.
Indexed as
Identifiers
42853365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.